High expression of COL6A1 predicts poor prognosis and response to immunotherapy in bladder cancer
Authors:
Open Access
- 6 December 2022
- journal article
- research article
- Published by Taylor & Francis in Cell Cycle
- Vol. 22 (5) , 610-618
Abstract
Extracellular matrix (ECM), as an important framework for tumor microenvironment, plays important roles in many critical processes, including tumor growth, invasion, immune suppression, and drug resistance. However, few biomarkers of ECM-related genes (ERGs) have been developed for prognosis prediction and clinical treatment of bladder cancer (BC) patients. Bioinformatics analysis and LC-MS/MS analysis were used to screen differentially expressed ERGs in BC. Multivariate Cox regression analysis and Lasso regression analysis were used to construct and validate an ERGs-based prognostic prediction model for BC. Immunohistochemistry was used to detect the protein expression of hub gene-COL6A1 in BC patients. Using bioinformatics analysis from The Cancer Genome Atlas (TCGA) database and proteomic analysis from our BC cohort, we constructed and validated an effective prognostic prediction model for BC patients based on four differentially expressed ERGs (MAP1B, FBN1, COL6A1, and MFAP5). Moreover, we identified human collagen VI-COL6A1 was a hub gene in this prognostic prediction model and found that COL6A1 was closely related to malignancy progression, prognosis, and response to PD-1 inhibitor immunotherapy in BC. Our findings highlight the satisfactory predictive value of ECM-related prognostic models in BC and suggested that COL6A1 may be a potential biomarker in predicting malignant progression, prognosis, and efficacy of immunotherapy in BC.Keywords
Funding Information
- National Natural Science Foundation of China (81972378, Nos.81101932)
This publication has 25 references indexed in Scilit:
- Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patientsOncotarget, 2015
- Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growthOncotarget, 2015
- Functional polarization of tumour-associated macrophages by tumour-derived lactic acidNature, 2014
- Imaging aspects of the tumor stroma with therapeutic implicationsPharmacology & Therapeutics, 2014
- FGFR1–WNT–TGF-β Signaling in Prostate Cancer Mouse Models Recapitulates Human Reactive StromaCancer Research, 2014
- Characterization of a rare case of Ullrich congenital muscular dystrophy due to truncating mutations within the COL6A1 gene C-Terminal domain: a case reportBMC Medical Genetics, 2013
- Quantitative Secretome Analysis Reveals that COL6A1 is a Metastasis-Associated Protein Using Stacking Gel-Aided Purification Combined with iTRAQ LabelingJournal of Proteome Research, 2010
- Identiication of COL6A1 as a differentially expressed gene in human astrocytomasGenetics and Molecular Research, 2008
- Of Extracellular Matrix, Scaffolds, and Signaling: Tissue Architecture Regulates Development, Homeostasis, and CancerAnnual Review of Cell and Developmental Biology, 2006
- Lymphangiogenesis and cancer metastasisNature Reviews Cancer, 2002